The evolving regulatory landscape in Latin America and the world reflects a commitment to strengthening regulatory systems, enhancing collaboration, and aligning with international standards with the ultimate goal of harmonisation. These efforts contribute to a more efficient, transparent, and patient-centered environment, fostering innovation, increasing access to medicines, and ultimately improving healthcare outcomes for populations all across in the region.

Successful technology-transfer programs led by multinational companies and advanced biotech hubs. It outlines how Colombia can integrate similar mechanisms to accelerate its transition from fill-finish activities to fully integrated bioprocess development and manufacturing.

Contract Manufacturing Organisations (CMOs) and Contract Development and Manufacturing Organisations (CDMOs) are vital in the global pharmaceutical market, but are notably rare in Latin America, while Contract Research Organisations (CROs) are more common.
Transitioning from small in-house projects and academic capabilities to a fully professional and validated scenario is a complex task. Competitiveness, encompassing costs of goods, timelines, success rates, and a global approach, remains a key challenge. Moreover, navigating the intellectual property landscape is crucial, as it impacts both the development of biosimilars and the capacity to offer related services. In Colombia and the rest of the region, they offer a promising way to bridge the gap between foreign investors and local infrastructure and demand.

A comparative analysis of the United States, Europe, Korea, and emerging markets, showing how policies, incentives, and procurement strategies significantly increased biosimilar penetration. The case study provides actionable insights Colombia can leverage to improve patient access and strengthen pricing sustainability.

Colombia is facing a new era in the local manufacturing of Biosimilars, To attract investors, it is crucial to raise international awareness, incentivise them to explore the advantages of the Colombian market and, in turn, to understand their concerns, interests, and expectations of investors considering Colombia as a viable market for biosimilar initiatives.

Provide a high-level strategic outlook on the current and emerging opportunities for biosimilars in Colombia, while addressing the critical challenges that influence market growth, regulatory alignment, local manufacturing capacity, pricing dynamics, and patient access. This C-level discussion aims to outline practical pathways for strengthening Colombia’s biosimilar ecosystem through collaboration among industry leaders, policymakers, payers, and healthcare providers.

Download Agenda